Bacterial Immunologists are specialized scientists who examine how the immune system detects, responds to, and eliminates bacterial pathogens. Their research focuses on understanding how immune cells, such as macrophages, neutrophils, and T cells, recognize and defend against bacteria that cause diseases. They study the various immune mechanisms that are activated during infection and investigate how bacteria, including Streptococcus pneumoniae, Mycobacterium tuberculosis, and Escherichia coli, evade immune detection or manipulate the immune response to establish persistent infections. This research is crucial for identifying new therapeutic targets and improving our understanding of bacterial pathogenesis.
Bacterial immunologists are at the forefront of developing vaccines and therapies aimed at bacterial diseases. Their work includes examining bacterial antigens, identifying ways to enhance immune activation, and designing novel vaccine strategies to offer long-term protection, especially against antibiotic-resistant bacteria. As antibiotic resistance becomes a growing global concern, bacterial immunologists are also exploring alternative immune-based treatments, such as monoclonal antibodies and immune modulators, to strengthen the body’s natural defense mechanisms. The expertise of bacterial immunologists is essential for advancing the development of vaccines and therapies that combat the global threat of bacterial infections. Their ongoing research is instrumental in shaping the future of infectious disease control and improving global public health.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States